Immunotherapy for hepatocellular carcinoma: Recent advances and future targets

Immunotherapy is a promising approach to treating various types of cancers, including hepatocellular carcinoma (HCC). While single immunotherapy drugs show limited effectiveness on a small subset of patients, the combination of the anti PD-L1 atezolizumab and anti-vascular endothelial growth factor bevacizumab has shown significant improvement in survival compared to sorafenib as a first-line treatment. However, the current treatment options still have a low success rate of about 30%. Thus, more effective treatments for HCC are urgently required. Several novel immunotherapeutic methods, including the use of novel immune checkpoint inhibitors, innovative immune cell therapies like chimeric antigen receptor T cells (CAR-T), TCR gene-modified T cells and stem cells, as well as combination strategies are being tested in clinical trials for the treatment of HCC. However, some crucial issues still exist such as the presence of heterogeneous antigens in solid tumors, the immune -suppressive environment within tumors, the risk of on-target/off-tumor, infiltrating CAR-T cells, immunosup-pressive checkpoint molecules, and cytokines. Overall, immunotherapy is on the brink of major advancements in the fight against HCC.(c) 2023 Elsevier Inc. All rights reserved.

Automated summary

Immunotherapy is a promising approach for treating cancers, including hepatocellular carcinoma (HCC). Current treatment options have a low success rate, and more effective methods are urgently needed. Novel immunotherapeutic methods, such as immune checkpoint inhibitors and immune cell therapies like CAR-T cells and stem cells, are being tested in clinical trials for the treatment of HCC. Overall, immunotherapy is on the brink of major advancements in fighting against HCC.